A Single-Dose, Placebo-Controlled, Stratified, Randomized, Double-Blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-Week Multiple-Dose Safety and Tolerability in People With Chronic Stable Schizophrenia.

Next Previous
Trial Profile

A Single-Dose, Placebo-Controlled, Stratified, Randomized, Double-Blind, Crossover to Study Pharmacodynamic Effects of AQW051 Followed by a 4-Week Multiple-Dose Safety and Tolerability in People With Chronic Stable Schizophrenia.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 03 Nov 2016

At a glance

  • Drugs AQW 051 (Primary)
  • Indications Schizophrenia
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 24 Apr 2012 Actual patient number is 68 according to ClinicalTrials.gov.
    • 24 Apr 2012 Actual end date (Nov 2011) added as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top